Arrowstreet Capital, Limited Partnership Beam Therapeutics Inc. Transaction History

Arrowstreet Capital, Limited Partnership

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $1.54 Million - $2.72 Million	38,699 Added 70.44%	93,640 $4.46 Million
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $1.07 Million - $2.23 Million	35,812 Added 187.21%	54,941 $2.13 Million
Q1 2022 May 13, 2022	BUY	$53.73 - $82.16 $1.03 Million - $1.57 Million	19,129 New	19,129 $1.1 Million
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $1.44 Million - $2.09 Million	-21,110 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$84.37 - $133.6 $1.78 Million - $2.82 Million	21,110 New	21,110 $1.84 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.